Lexaria Bioscience (LEXX) has released an update.
Lexaria Bioscience Corp. is actively pursuing a strategic growth plan, including expanding its management team and preparing for new R&D projects and a Phase 1b hypertension study. The company’s confidence in its medium-term and long-term strategies is bolstered by its ongoing success and the appointment of Nelson Cabatuan as the Chief Strategic Financial Advisor. Lexaria’s patented DehydraTECH technology continues to show promise in enhancing drug delivery.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
